Supplementary Data from A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
Salah-Eddine Bentebibel(The University of Texas MD Anderson Cancer Center), Adi Diab(Cleveland Clinic), Mario Sznol(Yale University), Jonathan Zalevsky(Nektar Therapeutics (United States)), Mary A. Tagliaferri(Nektar Therapeutics (United States)), Brendan D. Curti(Providence Portland Medical Center), Patrick Hwu(Moffitt Cancer Center), Ute Hoch(University of Arizona), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), Nizar M. Tannir(The University of Texas MD Anderson Cancer Center), Michael T. Tetzlaff(Hospital of the University of Pennsylvania), Michael E. Hurwitz(Yale University), Christie Fanton(Nektar Therapeutics (United States)), Harriet M. Kluger(Yale Cancer Center), Sandra Aung(Nektar Therapeutics (United States)), Courtney W. Hudgens(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
|Journal of Clinical Oncology|2014|2.2k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k